Mixed feelings for Covidien's Pipeline embolization device following deaths

Thu, 12/06/2012 - 9:41am
Mass Device

Researchers have words of praise and warning for Covidien subsidiary eV3's Pipeline cerebral aneurysm device after several patients suffer from fatal brain bleeds post-treatment.

eV3's Pipeline embolization device

Researchers offered mixed messages on the safety and effectiveness of Covidien (NYSE:COV) subsidiary ev3 Inc.'s Pipeline embolization device, lauding the system as an option for patients with aneurysms that may not otherwise be treatable but warning of a significant risk of serious complications.

Researchers conducting post-market research on the PED reported "promising results" for the treatment, which diverts blood away from a brain aneurysm and promotes vessel tissue growth that blocks off the aneurysm over time, rather than providing immediate occlusion.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.